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DLL3 prevents the localization of Notch and DLL1 (Notch activating ligand) to the cell surface via intracellular retainment. 6, 7 Thus, DLL3 is regarded as a cell autonomous inhibitor of Notch signaling. 3, 5 DLL3 is also expressed throughout the presomitic mesoderm and is localized to the rostral somatic compartments. 8, 9 Mutations in the DLL3 gene induce skeletal abnormalities in spondylocostal dysostosis. 10 It is reported that DLL3 is specifically expressed in the fetal brain. 11, 12 Our previous findings indicated that DLL3 expression was frequently silenced by epigenetic modifications such as aberrant DNA methylation and histone acetylation in hepatocellular carcinoma (HCC) cells, 2, 13 and DLL3 expression induced apoptosis in HCC cells. 2 Moreover, hepatitis B virus (HBV) protein (HBx) caused epigenetic modifications and suppressed the expression of DLL3 in HBV-associated HCC. 14 Recently, the discovery of elevated DLL3 expression on the cell surface of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) cells has prompted investigation into the potential targeting of DLL3 for novel lung cancer treatments, and a DLL3-targeting antibody-drug conjugate (rovalpituzumab tesirine: Rova-T) showed tumor regression effects in SCLC and LCNEC. 12, 15 These recent results suggest that DLL3 is deeply associated with the oncological processes of NEC. However, the expression pattern and functions of DLL3 in the gastrointestinal (GI) tract are largely unknown. In this study, we aimed to clarify the expression and roles of DLL3 in the GI tract, including in GI-NEC.
| MATERIAL S AND ME THODS

| Patient samples
Gastrointestinal tissues were obtained from specimens following surgery at the Department of General and Gastroenterological Surgery, Osaka Medical College (Takatsuki). All samples were obtained after receiving written informed consent from the patients.
This study was reviewed and approved by the institutional review board (IRB) of Osaka Medical College (acceptance number: 2535), in accordance with the tenets of the Declaration of Helsinki. The details regarding patient clinical features are shown in Tables 1 and S1. 
| Cell lines, cell culture and cell viability
| Immunohistochemistry
Immunohistochemistry (IHC) was performed on 5-μm-thick formalin-fixed, paraffin-embedded tissue sections mounted on adhesive glass slides (Thermo Fisher Scientific). The slides were deparaffinized with xylene and hydrated with an ethanol series.
Then, the specimens were pretreated with antigen retrieval using heat-induced epitope retrieval methods, and endogenous per- using the same methods (Data S1).
| Double fluorescent immunohistochemistry
Following the IHC procedure described above, the slides were incubated with Protein Block Serum-Free X0909 (DAKO) for 40 minutes to block any nonspecific binding of the immunoreagents.
Next, the primary anti-DLL3 antibody (ab103102 1:500 dilution;
Abcam) and chromogranin A (code-Nr. M 0869 1:250 dilution: DAKO) were placed onto the same slides, and the slides were incubated overnight at 4°C. After washing in PBS, the slides were incubated with the goat anti-rabbit Alexa 488 and goat anti-mouse Alexa 594 secondary antibodies (Invitrogen Life Technologies) for 1 hour and counterstained with VECTASHIELD H1500 with DAPI (VECTOR Laboratories). They were visualized using a laser scanning microscope (Leica TCS SP8) and images were captured with LAS X software (Leica).
| Double fluorescent immunocytochemistry
Each ECC cell was seeded in a Lab-Tek II chamber slide system (Thermo Fisher Scientific) and fixed with 4% paraformaldehyde in PBS for 10 minutes, blocked for 40 minutes, and incubated with the anti-DLL3 antibody (ab103102 1:500 dilution, Abcam) and
anti-chromogranin A (code-Nr. M 0869 1:250 dilution, DAKO) overnight at 4°C. Then, the results were obtained through the same processes of double fluorescent IHC described above.
| Transmission electron microscopy
Each ECC cell was harvested, rinsed with PBS, and fixed for 2 hours with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer (PB, pH 7.4), rinsed in PB, and subsequently fixed in 1% OsO 4 for 2 hours. After washing with PB, the samples were dehydrated in a series of graded ethanol, cleared in propylene oxide, and embedded in epoxy resin mixture. Thereafter, ultrathin sections (70-nm thickness) were prepared, stained with uranyl acetate and lead citrate, and examined by transmission electron microscopy (TEM) with a Hitachi-7650 (Hitachi). 
| Immuno-electron microscopy
| Western blotting
Whole cells were homogenized in chilled radio-immunoprecipita- Predesigned TaqMan fluorogenic probes and primer sets for DLL3
(Hs01085096) and GAPDH (Hs03929097) were purchased from Applied Biosystems (Thermo Fisher Scientific). Relative quantification of DLL3 was normalized to the expression of GAPDH using the ∆∆Ct method. Supporting experiments were performed using the same methods (Data S1). 
| Transfection experiments
| Hoechst 33342 staining
Cells transfected with siRNA for 96 hours were detached and washed with ice-cold PBS. The cells were then stained with 5 μg/mL of Hoechst 33342 (Sigma-Aldrich) at 37°C for 1 hour, washed once with PBS, resuspended, pipetted dropwise onto a glass slide, and examined by fluorescence microscopy using a BZ-x700 (KEYENCE) equipped with an epi-illuminator and appropriate filters. The cells with condensed and/or fragmented nuclei stained with Hoechst 33342 were determined to be apoptotic. The number of apoptotic cells among 300 cells was counted.
| Caspase inhibitor experiments
Caspase inhibitor Z-VAD-FMK was obtained from Medical & Biological Laboratories. ECC4 and ECC10 cells were treated with Z-VAD-FMK for 6 hours before transfection with siR-DLL3 #2. The effects were assessed at 96 hours after transfection. Cell viability and the expression of apoptosis-related proteins were examined. 
| Three-dimensional spheroid colorimetric viability assay
| Statistical analysis
Each examination was performed in triplicate. The statistical significance of differences was evaluated by performing the 2-sided Student's t-test. The values are presented as the mean ± standard deviation. A P-value < 0.05 was considered to be statistically significant.
| RE SULTS
| The expression of DLL3 was localized to the deep layer mucosa cells in the gastrointestinal tract
First, DLL3 expression in the GI tract, including the stomach, duodenum, jejunum, ileum and rectum, was examined by IHC. Our results showed that DLL3 was expressed in the cytoplasm of the cells at the deep layer of the mucosa in the GI tract ( Figure 1A-F ).
Chromogranin A (CHGA) is a representative marker of neuroendocrine cells. [16] [17] [18] [19] Interestingly, IHC of serial tissue sections showed that the locations of DLL3 and CHGA were similar in the specimens tested (Figure 2A-E) . To further clarify our findings, double fluorescence IHC was performed on tissue sections of normal stomach and duodenum. This demonstrated that the expression of DLL3 and CHGA was synchronized. In other words, DLL3 was expressed in CHGA-positive cells (Figure 3A,B ).
| DLL3 expression was associated with neuroendocrine cancer cells of gastrointestinal tract
Next, we tried to ascertain the expression of DLL3 in neuroendocrine-related GI cancer cells. Endocrine marker (CHGA)-positive gastric cancer specimens were selected (cases 1-4, Table 1 ). As shown in Figure 4A , DLL3 was strongly expressed in these specimens.
Furthermore, DLL3 was strongly expressed in GI-NEC (mixed adenoneuroendocrine carcinoma; MANEC) specimens (cases 5 and 6, Table 1 ) ( Figure 4A ). Importantly, in the serial tissue sections of these specimens, the expression of DLL3 was positive in the CHGA-positive cancer cells ( Figures 4B, S1 ).
| The expression levels of DLL3 were upregulated in gastrointestinal-neuroendocrine carcinoma cells
To examine the mRNA expression level of DLL3, RT-qPCR was performed on GI-NEC cell lines; namely, ECC4, ECC10 and ECC12 cells. in other cancer cell lines tested ( Figure 5A ). The same tendency was observed in the protein expression levels of DLL3 by western blot analysis ( Figure 5B ). Interestingly, DLL3 mRNA expression levels of ECC cells were comparable to those of SCLC cells ( Figure S2 ). Double fluorescent immunocytochemistry (ICC) showed that the localization of DLL3 and CHGA was similar in the cytoplasm as in the clinical specimens ( Figure 6A ). Interestingly, our ICC staining with electron microscopy showed that DLL3 was expressed in neurosecretory granules ( Figure 6B ,C).
| Knockdown of DLL3 inhibited cell growth through the induction of apoptosis in gastrointestinalneuroendocrine carcinoma cells
To analyze the functions of DLL3 in GI-NEC cells, we performed gene silencing of DLL3 in these cell lines. As shown in Figure 7A , significant growth inhibition was observed in siR-DLL3-treated GI-NEC cells. The expression levels of cleaved PARP and caspase 3 were increased in these cells ( Figure 7B ). Interestingly, cleaved caspase 9 expression levels, which indicate an induction of intrinsic apoptosis, were also increased ( Figure 7B ). Furthermore, Hoechst 33342 staining showed that the number of apoptotic cells was increased in siR-DLL3-treated ECC cells ( Figure 7C ). The pan-caspase inhibitor Z-VAD-FMK significantly recovered cell growth and suppressed 
| D ISCUSS I ON
Previous evidence showed that DLL3 played important roles in embryonic development. 4 In the last few years, DLL3 has been identified as a novel therapeutic target gene, and the anti-tumor effectiveness and safety of DLL3-targeting antibody-drug conjugate (Rova-T) have been demonstrated through a clinical trial for SCLC and LCNEC. 15, 20 Importantly, elevated expression of DLL3 was detected in more than 80% of patients with SCLC. 15 Our findings in this study indicated that the considerable upregulation of DLL3 expression was consistent even in GI-NEC cells (Figures 4,5, S2 ). Thus, it is possible that upregulation of DLL3 expression universally occurs during carcinogenesis of NEC and that DLL3 is one of the essential genes in various NEC.
In this study, we used CHGA as a positive marker of neuroendocrine cells. Granins are an acidic protein family that constitute a major component of secretory granules of various endocrine cells including neuroendocrine cells. This family is composed of 8 granin proteins (ie, chromogranin A, B, C, secretogranin (III, IV, V, VI) and VEGF). 16 Among these, CHGA is the first identified granin and is produced and excreted by granules within both endocrine glands and the diffused neuroendocrine system. [16] [17] [18] [19] In fact, ECC cell lines used in the present study had abundant neurosecretory granules. 21 Importantly, the expression pattern of DLL3 was similar to that of CHGA in both clinical samples (Figures 2, 3 and 4 ) and
ECC cell lines ( Figure 6A) , and, in particular, our immuno-electron microscopy clearly indicated that DLL3 was expressed in neurosecretory granules (Figure 6B,C) . These findings support the hypothesis that DLL3 is a novel neuroendocrine-associated gene in the GI tract ( Figure 8 ).
In other cancers types, our group proved that DLL3 was suppressed in HCC. 14 In contrast, the expression levels of DLL3 were increased in pancreatic ductal adenocarcinoma. 22 Therefore, the roles of DLL3 seem to depend on the cancer type. Interestingly, upregulation of DLL3 was reported in cancer of the pancreas, which is one of the endocrine-related representative organs. Further investigation will clarify in detail the association between DLL3 and neuroendocrine cells. In addition, the determination of DLL3-regulating mechanisms, especially in GI-NEC cells, is required.
Moreover, in NEC cells, DLL3 knockdown might have a critical influence through the induction of intrinsic apoptosis (Figure 7) . It in GI-NEC cells is necessary. In addition, the effects of ROVA-T in GI-NEC cells should be investigated in consideration of the location of DLL3 expression. 7, 24 The findings of this study may contribute to a breakthrough in therapeutic strategies for GI-NEC.
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